DPIIT recognised startup Government of India
Startup India
Bycus Therapeutics Private Limited - life sciences in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹3.98 Cr
▲ 66823% YoY
Net loss · FY 2025
₹1.39 Cr
Net margin -35%
EBITDA · FY 2025
-₹88.88 Lakh
EBITDA margin -22.3%
Authorised capital
₹40 Lakh
Registered with MCA
Paid-up capital
₹23.26 Lakh
Issued & subscribed
Company age
6 yrs
Est. 2020
Employees · EPFO
46
Provident fund records
Directors on board
3
As per MCA filings
About Bycus Therapeutics Private Limited
Data last updated:
Bycus Therapeutics Private Limited is a private limited company based in Hyderabad, Telangana, India, recognised as a startup by DPIIT. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 23 April 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U73200TG2020PTC140175. Its GSTIN is 36AAICB9869P1ZK (Telangana).
The company has an authorised share capital of ₹40 Lakh and a paid-up capital of ₹23.26 Lakh. It is led by directors including Nageswara Rao Pulipati and Nishanth Pasaru.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Suite No.13 Ouh Bio – Nest School Of Lifesciences C/O University Of Hyderabad, Telangana, India – 500046.
As per the financials filed for FY 2025, the company reported a revenue of ₹3.98 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹1.39 Cr (net margin -35%) and EBITDA of -₹88.88 Lakh (EBITDA margin -22.3%). Revenue has grown at a compounded annual rate (CAGR) of 162% over three years.
The company has about 46 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: ByCus. The company has 2 deals on record (1 rights issue, 1 funding round), with disclosed funding of ₹12.5 Cr; the latest was in March 2022. Its 3 peer companies in the Biotechnology industry (Biotechnology), with the same principal business activity (scientific research and development) are compared by revenue, 1 larger and 2 smaller; the largest is Skanda Lifesciences Private Limited with revenue of ₹4.02 Cr.
Bycus Therapeutics Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-09-0015784). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bycusbio.com.
Company details
CIN U73200TG2020PTC140175
Registration Number 140175
Incorporation Date 23 April 2020
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
DPIIT Recognition Recognised Startup
MSME Classification Micro
Udyam Registration UDYAM-TS-09-0015784
Recognitions & Rankings of Bycus Therapeutics
MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2023-24)
- Udyam number
- UDYAM-TS-09-0015784
Contact details
Bycus Therapeutics Private Limited's registered office is in Hyderabad, Telangana. Its website is bycusbio.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressSuite No.13 Ouh Bio – Nest School Of Lifesciences C/O University Of Hyderabad, Telangana, India – 500046
- IndustryLife Sciences, Biotechnology
To see the full contact details of Bycus Therapeutics Private Limited, buy the company report.
Comprehensive company report
Bycus Therapeutics Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Bycus Therapeutics operates one associated brand: ByCus. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Company that develops drug substances and products focused on patient care and medical advancements | bycusbio.com |
Business activity
The main business activity of Bycus Therapeutics is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Bycus Therapeutics Private Limited, buy the company report.
Financials of Bycus Therapeutics Private Limited
FY 2025 filings availableBycus Therapeutics Private Limited reported revenue of ₹3.98 Cr (up 66823% YoY) for FY 2025.
Revenue · FY 2025
₹3.98 Cr ▲ 66823%
Net loss · FY 2025
₹1.39 Cr margin -35%
EBITDA · FY 2025
-₹88.88 Lakh margin -22.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
3 years · compounded
▲ 162%
EBITDA CAGR growth
1 year
▼ 114%
3 years · compounded
▼ 107%
Revenue has grown at a compounded annual rate (CAGR) of 162% over three years. EBITDA fell 114% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹88.88 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹1.39 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -22.3% | ||||
| Net Profit Margin | -35% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Bycus Therapeutics Private Limited, buy the company report.
Board of directors of Bycus Therapeutics Private Limited
Bycus Therapeutics has 3 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nageswara Rao Pulipati Also directs: Bycus Bio Sciences LLP | Director | 23 Apr 2020 | 6 Years 6 Months | Current |
| Nishanth Pasaru Also directs: Bycus Bio Sciences LLP, Dr Agri Bio Innovations Private Limited | Director | 23 Apr 2020 | 6 Years 6 Months | Current |
| Lavanya Sunkara Also directs: Bycus Bio Sciences LLP, Dr Agri Bio Innovations Private Limited | Director | 23 Apr 2020 | 6 Years 6 Months | Current |
Peer comparison
Bycus Therapeutics Private Limited is compared with the 3 companies closest to it by revenue in the Biotechnology industry (Biotechnology), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Skanda Lifesciences Private Limited | ₹4.02 Cr (FY 2025) | 16.0% | Bangalore, Karnataka, India | |||
| Bycus Therapeutics Private Limitedthis company | ₹3.98 Cr (FY 2025) | -₹1.39 Cr | -35% | 66823.0% | 46 | Hyderabad, Telangana, India |
| Navya Biologicals Private Limited | ₹3.95 Cr (FY 2016) | 108.0% | Bangalore, Karnataka, India | |||
| Krishi Bounty Private Limited | ₹3.9 Cr (FY 2025) | 182.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Bycus Therapeutics Private Limited, buy the company report.
Auditor
Bycus Therapeutics Private Limited is audited by D S RAJ PUROHIT & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| D S RAJ PUROHIT & ASSOCIATES | FY 2023 | 015691S |
Shareholding
The shareholding of Bycus Therapeutics Private Limited is on record for 3 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Bycus Therapeutics Private Limited, buy the company report.
Deals & funding
Bycus Therapeutics Private Limited has 2 deals on record (1 rights issue, 1 funding round), with disclosed funding of ₹12.5 Cr; the latest was in March 2022.
Total deals
2
Rights issue
1
Funding round
1
Disclosed funding
₹12.5 Cr
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Funding round · Seed | ₹12.5 Cr | Investors: Relentless Bio Sciences LLP |
| Mar 2022 | Rights issue | ₹1.6 Lakh | Investors: Bycus Bio Sciences LLP |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Bycus Therapeutics Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Bycus Therapeutics Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Bycus Therapeutics Private Limited has a workforce of 46 employees on its EPFO records as of Mar 30, 2024, across 1 active EPFO establishment.
Employee count
46
Active EPFO establishments
1
Employee growth
35.29%
GST
Bycus Therapeutics has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAICB9869P1ZK | Telangana | Active | 19 May 2020 |
To see the full GST registrations and return filing status of Bycus Therapeutics Private Limited, buy the company report.
Recent activity
Bycus Therapeutics Private Limited has 3 board changes on record since 2020: 3 appointments. The latest: Lavanya Sunkara was appointed as Director on 23 Apr 2020.
AGM
Bycus Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Bycus Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Appointed
Lavanya Sunkara was appointed as Director.
Appointed
Nageswara Rao Pulipati was appointed as Director.
Appointed
Nishanth Pasaru was appointed as Director.
Incorporation
23 Apr 2020
Bycus Therapeutics Private Limited was registered on 23 Apr 2020 with Roc Hyderabad & aged 6 years 6 months as per MCA records.
Frequently asked questions
Bycus Therapeutics is an active private limited company based in Hyderabad, Telangana, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 23 April 2020 (6+ years old) and is registered under CIN U73200TG2020PTC140175.
Bycus Therapeutics has 3 current directors:
- Nageswara Rao Pulipati - Director
- Nishanth Pasaru - Director
- Lavanya Sunkara - Director
The latest financial statements of Bycus Therapeutics on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Bycus Therapeutics is 36AAICB9869P1ZK, registered in Telangana.
The CIN (Corporate Identification Number) of Bycus Therapeutics is U73200TG2020PTC140175. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Bycus Therapeutics was incorporated on 23 April 2020, making it 6+ years old. It is registered with the Registrar of Companies, Hyderabad.
Bycus Therapeutics has 2 deals on record (1 rights issue, 1 funding round), with disclosed funding of ₹12.5 Cr; the latest was in March 2022.
The peers of Bycus Therapeutics by revenue are Skanda Lifesciences Private Limited, Navya Biologicals Private Limited, Krishi Bounty Private Limited, all in the Biotechnology industry (Biotechnology), with the same principal business activity (scientific research and development).
Lavanya Sunkara was appointed as Director on 23 Apr 2020. Nageswara Rao Pulipati was appointed as Director on 23 Apr 2020. Nishanth Pasaru was appointed as Director on 23 Apr 2020.
Yes, Bycus Therapeutics is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Yes, Bycus Therapeutics is registered as a micro enterprise under Udyam registration (number: UDYAM-TS-09-0015784).